Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Automatically detect candlestick patterns on any chart

Read How
Market News Market Pulse Stocks News ETF News Crypto News

Purple Biotech Ltd.

Contributing Author

Recent Articles by Purple Biotech Ltd.

35 min
New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies PPBT +15.06% GlobeNewswire
Aug-07
Purple Biotech Reports Second Quarter 2026 Financial Results PPBT GlobeNewswire
Jun-11
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window PPBT -47.97% GlobeNewswire
May-15
Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights PPBT +6.78% GlobeNewswire
Apr-27
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240 PPBT GlobeNewswire
Apr-23
Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform PPBT -8.08% GlobeNewswire
Mar-25
Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform PPBT GlobeNewswire
Mar-17
Purple Biotech Regains Compliance with Nasdaq PPBT GlobeNewswire
Mar-13
Purple Biotech Announces CEO Transition PPBT +6.77% GlobeNewswire
Mar-13
Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results PPBT +6.77% GlobeNewswire
Feb-25
Purple Biotech Announces Plan to Implement ADS Ratio Change PPBT GlobeNewswire
Jan-07
Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240 PPBT GlobeNewswire
Dec-11
Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025 PPBT GlobeNewswire
Dec-04
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress PPBT +8.17% GlobeNewswire
Nov-14
Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update PPBT GlobeNewswire
Oct-29
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform PPBT +81.82% GlobeNewswire
Oct-20
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification PPBT GlobeNewswire
Sep-10
Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance PPBT -5.28% GlobeNewswire
Sep-05
Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants PPBT -15.38% PPBT -9.24% GlobeNewswire
Sep-04
Purple Biotech Announces Pricing of Up To $18 Million Public Offering PPBT -45.07% GlobeNewswire
Sep-04
Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai PPBT -45.07% GlobeNewswire
Sep-03
Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2 PPBT GlobeNewswire
Aug-27
Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference PPBT GlobeNewswire
Aug-06
Purple Biotech Reports Second Quarter 2025 Financial Results PPBT GlobeNewswire
Jul-23
Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025 PPBT GlobeNewswire
Jun-23
Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress PPBT GlobeNewswire
Jun-17
Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer PPBT GlobeNewswire
Jun-04
Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform PPBT GlobeNewswire
May-21
Purple Biotech Reports First Quarter 2025 Financial Results PPBT GlobeNewswire
May-12
Purple Biotech Appoints Shai Lankry as Chief Financial Officer PPBT GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)